PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS

Zhou, Jihao1; Zuo, Min2; Li, Lifeng3; Li, Fang4; Ke, Peng1; Zhou, Yangying5; Xu, Yaping3; Gao, Xuan3; Guan, Yanfang3; Xia, Xuefeng3; Yi, Xin3; Zhang, Xinyou1; Huang, Yuhua6,7

2022-02-09

10.3389/fonc.2022.824632

Frontiers in Oncology   影响因子和分区

2234-943X

Primary diffuse large B cell lymphoma of the central nervous system (CNS DLBCL) is a rare malignancy with a distinct genetic profile. The clinicopathological significance of the mutation patterns remains unknown. Forty cases of primary CNS DLBCL were subjected to targeted exome sequencing covering 413 genes, including MYD88, CD79B and PIM1. Mutational analysis recognized two groups. The CDP (including CD79B and/or PIM1mutations) group was identified in 27 cases (67.5%), and the non-CDP (without CD79B and PIM1 mutations) group was identified in 13 cases 32.5%). The CDP group tended to occur in older patients (median age 57.0 vs. 48.4 years, p=0.015). Patients in the CDP group had a significantly longer 2-year overall survival (OS) (76% and 40%, p=0.0372) than those in the non-CDP group. Multivariate analysis revealed that age less than 60 years, no MYC and BCL2 double expression, and CDP group were three independent risk factors indicating favorable OS. PyClone analysis revealed the subcloning heterogeneity between the groups. In addition, transcriptional sequencing was successfully performed in 8 cases. A total of 131 genes were significantly differentially expressed between these two groups. The major categories of biological processes that were significantly altered between these two groups related to intracellular metabolism mechanisms. We developed a new molecular classification to divide CNS DLBCL into CDP and non-CDP groups based on CD79B and PIM1 mutational status. Patients with PIM1 and/or CD79B mutations had favorable long-term survival after high-dose methotrexate-based polychemotherapy.

central nervous system diffuse large B-cell lymphoma molecular classification PIM1 CD79B

SCI

英语

第一 ; 通讯

National Natural Science Foundation of China[81600168,81702082] ; Sanming Project of Medicine in Shenzhen[SZSM201512006] ; Medical Science and Technology Foundation of Guangdong Province[A2019401]

Oncology

Oncology

WOS:000760684600001

FRONTIERS MEDIA SA

Web of Science

1.Southern Univ Sci & Technol, Jinan Univ, Shenzhen Peoples Hosp, Dept Hematol,Affiliated Hosp 1,Clin Med Coll 2, Shenzhen, Peoples R China
2.Southern Univ Sci & Technol, Jinan Univ, Shenzhen Peoples Hosp, Dept Pathol,Affiliated Hosp 1,Clin Med Coll 2, Shenzhen, Peoples R China
3.Geneplus Beijing, Med Ctr, Beijing, Peoples R China
4.Geneplus Beijing Inst, Beijing, Peoples R China
5.Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Peoples R China
6.Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China
7.Sun Yat Sen Univ, Dept Pathol, Canc Ctr, Guangzhou, Peoples R China

Zhou, Jihao,Zuo, Min,Li, Lifeng,et al. PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS[J]. Frontiers in Oncology,2022,12.

Zhou, Jihao.,Zuo, Min.,Li, Lifeng.,Li, Fang.,Ke, Peng.,...&Huang, Yuhua.(2022).PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS.Frontiers in Oncology,12.

Zhou, Jihao,et al."PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS".Frontiers in Oncology 12(2022).